Alerts will be sent to your verified email
Verify EmailINDOCO
Indoco Remedies
|
Panacea Biotec
|
Novartis
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
54.0 . | 6.0 . | n/a |
Number of ANDA's Approved By USFDA
|
32.0 . | n/a | n/a |
Domestic Sales Growth - YoY
|
4.0 % | n/a | -5.28 % |
US DMF Filings
|
26.0 . | n/a | n/a |
Global DMFs filed
|
147.0 . | n/a | n/a |
R&D as a % of Total Sales
|
5.7 % | 9.86 % | n/a |
Financials
|
|||
5 yr Average ROE
|
8.94 % | 17.16 % | 8.0 % |
5yr average Equity Multiplier
|
1.9 | 1.61 | 2.72 |
5yr Average Asset Turnover Ratio
|
0.88 | 0.4 | 0.18 |
5yr Avg Net Profit Margin
|
5.41 % | 19.26 % | 17.12 % |
Price to Book
|
2.72 | 3.13 | 2.85 |
P/E
|
0.0 | 227.93 | 21.77 |
5yr Avg Cash Conversion Cycle
|
35.3 Days | -102.87 Days | -23.33 Days |
Inventory Days
|
70.6 Days | 109.97 Days | 44.27 Days |
Days Receivable
|
83.16 Days | 37.7 Days | 38.18 Days |
Days Payable
|
111.01 Days | 294.14 Days | 124.28 Days |
5yr Average Interest Coverage Ratio
|
7.53 | 2.9 | 65.43 |
5yr Avg ROCE
|
13.6 % | -1.68 % | 5.91 % |
5yr Avg Operating Profit Margin
|
14.97 % | -1.99 % | 15.15 % |
5 yr average Debt to Equity
|
0.49 | 0.05 | 0.0 |
5yr CAGR Net Profit
|
n/a | -64.03 % | 37.01 % |
5yr Average Return on Assets
|
5.31 % | 6.95 % | 3.13 % |
Shareholdings
|
|||
Promoter Holding
|
58.9 % | 72.48 % | 70.68 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.21 % | -1.11 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
1.16 % | 0.0 | 0.0 |
Indoco Remedies
|
Panacea Biotec
|
Novartis
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|